top of page

aTyr Pharmaceuticals, Athena & Scientella Join Forces to Ignite STEM Innovation

Updated: Mar 20

Athena, a global women's advocacy organization that fast-tracks professional women in STEM, is pleased to announce a strategic alliance with Scientella, a national non-profit organization providing young girls and women with STEM education and talent development, and aTyr, a clinical-stage biotechnology company. This collaboration aims to fortify the next generation of STEM innovators by exposing the national pipeline of STEM students to conduct primary and secondary research projects in collaboration with leading STEM companies.

"As Athena expands globally, this partnership will nurture the flow of emerging STEM talent and further the identification of STEM careers among girls and young women as the alliance bridges real-world experiential learning across Athena’s portfolio of STEM corporate partners," Athena's CEO, Holly Smithson explains.

"This partnership pairs two STEM organizations dedicated to training, mentoring, and matching talent with innovative solutions, Scientella General Manager, Raquel dos Santos explains, as this collaboration serves as a win-win for students and companies alike, she adds. "By leveraging both organizations' strengths, we’re fostering a future where a diverse pipeline of talent and opportunity fuels STEM innovation."

"As a longtime Athena corporate partner and dedicated advocate for workplace equality in the life sciences sector, aTyr is excited to partner with Scientella to support their mission to develop young women into future STEM leaders," Eileen Sun, aTyr’s Sr. Director Program Management added. 

Key Highlights of the Alliance:

  1. Enhanced Mentorship Programs: The collaboration will result in expanded mentorship programs, connecting seasoned STEM companies with students to provide guidance, insights, and support throughout their educational and professional journeys.

  2. Strategic Talent Matching: Athena and Scientella will work hand in hand to match STEM students with companies seeking diverse and skilled talent, fostering an environment where innovation thrives.

  3. Innovative Training Initiatives: Joint efforts will be undertaken to develop cutting-edge training programs that address the evolving needs of the STEM workforce, ensuring that individuals are equipped with the skills required for success.

  4. Diversity and Inclusion Advocacy: The alliance will actively champion diversity and inclusion in STEM fields, striving to create an environment where individuals from all backgrounds can thrive and contribute to groundbreaking advancement

About Athena

Athena is a global women's advocacy organization that fast-tracks women in STEM through leadership development, mentoring, and advocacy initiatives. By transforming women working in STEM into corporate leaders, the goal is to widen the bridge to advance 1 million women in STEM by 2030. Its 25-year history of advancing women in a global STEM hub marks Athena as a premier women’s empowerment advocate. To learn more, please visit

About Scientella

Scientella is a student-run, adult-guided organization that empowers the next generation of women STEM innovators by matching girls and young women with real-world career discovery and impact-minded leadership development opportunities.

About aTyr

aTyr is a clinical-stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit


bottom of page